S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NYSE:HRC - Hill-Rom Stock Price, Forecast & News

$102.25
-1.04 (-1.01 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$101.37
Now: $102.25
$103.74
50-Day Range
$102.25
MA: $110.32
$116.37
52-Week Range
$93.88
Now: $102.25
$117.10
Volume1.08 million shs
Average Volume475,051 shs
Market Capitalization$6.85 billion
P/E Ratio46.06
Dividend Yield0.81%
Beta0.88
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP43147510
Phone312-819-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$7.86 per share
Book Value$23.55 per share

Profitability

Net Income$152.20 million

Miscellaneous

Employees10,000
Market Cap$6.85 billion
Next Earnings Date4/24/2020 (Estimated)
OptionableOptionable

Receive HRC News and Ratings via Email

Sign-up to receive the latest news and ratings for HRC and its competitors with MarketBeat's FREE daily newsletter.


Hill-Rom (NYSE:HRC) Frequently Asked Questions

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom announced a quarterly dividend on Friday, November 8th. Stockholders of record on Monday, December 16th will be given a dividend of $0.21 per share on Tuesday, December 31st. This represents a $0.84 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend is Friday, December 13th. View Hill-Rom's Dividend History.

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) released its quarterly earnings data on Friday, January, 24th. The medical technology company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. The medical technology company earned $685 million during the quarter, compared to analyst estimates of $684.01 million. Hill-Rom had a return on equity of 21.87% and a net margin of 5.15%. Hill-Rom's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 earnings per share. View Hill-Rom's Earnings History.

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Hill-Rom.

What guidance has Hill-Rom issued on next quarter's earnings?

Hill-Rom updated its FY20 earnings guidance on Friday, January, 24th. The company provided EPS guidance of $5.50-5.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.52. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.94 billion.

What price target have analysts set for HRC?

3 brokerages have issued twelve-month price objectives for Hill-Rom's shares. Their forecasts range from $116.00 to $138.00. On average, they expect Hill-Rom's share price to reach $127.50 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Hill-Rom.

What is the consensus analysts' recommendation for Hill-Rom?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

What are Wall Street analysts saying about Hill-Rom stock?

Here are some recent quotes from research analysts about Hill-Rom stock:
  • 1. According to Zacks Investment Research, "Hill-Rom exited the second quarter of fiscal 2019 on a strong note with better-than-expected numbers. The company saw a solid year-over-year increase in domestic revenues, driven by sturdy performance in Patient Support Systems and Front Line Care. We are upbeat to note the company’s strong momentum across its diversified product portfolio which includes  Centrella Smart+ bed, Welch AllynConnex Spot Monitor, Monarch Airway Clearance System, Integrated Table Motion for the da Vinci Xi Surgical System. The acquisition of Voalte buoys optimism as it boosts Hill-Rom’s digital and mobile communications platform. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenue growth was sluggish in the quarter." (6/6/2019)
  • 2. Needham & Company LLC analysts commented, "HRC announced that it has entered into a definitive agreement to acquire Voalte (private) for $180M up front and up to $15M in commercial-based milestones. HRC believes it can absorb the dilutive impact of the deal in FY19, expects the transaction to close in F3Q19, and estimates the deal to become increasingly accretive beginning in FY20. Voalte offers smartphone and web-based applications that enable caregivers to communicate securely and provides managers data analytics tools, respectively. The Voalte deal seems to make financial (accretive to revenue growth and margins) and strategic (further diversifies HRC away from capital equipment sales and allows for cross-selling opportunities in its care communications business) sense, in our view, and we reiterate our Buy rating." (3/11/2019)

Has Hill-Rom been receiving favorable news coverage?

News coverage about HRC stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hill-Rom earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Hill-Rom.

Are investors shorting Hill-Rom?

Hill-Rom saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,620,000 shares, a decline of 12.4% from the December 31st total of 1,850,000 shares. Based on an average daily volume of 392,500 shares, the days-to-cover ratio is presently 4.1 days. Approximately 2.4% of the company's shares are sold short. View Hill-Rom's Current Options Chain.

Who are some of Hill-Rom's key competitors?

What other stocks do shareholders of Hill-Rom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO).

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the folowing people:
  • Mr. John P. Groetelaars, Pres, CEO & Director (Age 52)
  • Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 60)
  • Mr. Paul Johnson, Sr. VP & Pres of Patient Support Systems (Age 54)
  • Mr. Steven J. Strobel, Sr. Advisor (Age 61)
  • Ms. Barbara W. Bodem, Sr. VP & CFO (Age 51)

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (2.76%), State Street Corp (2.48%), Bank of New York Mellon Corp (1.63%), Bank of Montreal Can (1.58%), Geode Capital Management LLC (1.41%) and Bank of America Corp DE (1.24%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

Which major investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Jennison Associates LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Credit Suisse AG, Lord Abbett & CO. LLC, AQR Capital Management LLC and State Street Corp. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

Which major investors are buying Hill-Rom stock?

HRC stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., AXA, State of New Jersey Common Pension Fund D, Acadian Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Hill-Rom.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $102.25.

How big of a company is Hill-Rom?

Hill-Rom has a market capitalization of $6.85 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.

What is Hill-Rom's official website?

The official website for Hill-Rom is http://www.hill-rom.com/.

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]


MarketBeat Community Rating for Hill-Rom (NYSE HRC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  379 (Vote Underperform)
Total Votes:  742
MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel